Biomarkers Of Outcomes In A Randomized Phase Ii Trial Of First-Line Paclitaxel, Ifosfamide, And Cisplatin (Tip) Versus Bleomycin, Etoposide, And Cisplatin (Bep) For Intermediate- And Poor-Risk Germ Cell Tumors (Gct).

JOURNAL OF CLINICAL ONCOLOGY(2019)

引用 1|浏览46
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要